熱門資訊> 正文

Exact Sciences为其结直肠癌检测获得医疗保险

2025-07-09 21:14

Exact Sciences (NASDAQ:EXAS) has announced that its oncodetect test for detecting residual disease in colorectal cancer is now covered by Medicare.
This coverage is provided through the Centers for Medicare & Medicaid Services’ program for molecular diagnostics, allowing the test to be used repeatedly for patients with stage II, III, and resectable stage IV colorectal cancer during follow-up and monitoring over five years.

More on Exact Sciences

Exact Sciences Q1 Earnings: Decent Quarter, But Growth Story Not Compelling
Exact Sciences Corporation 2025 Q1 - Results - Earnings Call Presentation
Exact Sciences Corporation (EXAS) Q1 2025 Earnings Call Transcript
Exas, Guardant, Gilead among gainers as Supreme Court ensures free preventive care
Exact sciences raises 2025 revenue guidance to $3.12B driven by Cologuard Plus launch

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。